A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

The goal of this clinical trial is to evaluate the safety and response of combining Pirtobrutinib and Glofitimab in patients with relapsed MCL. The main question it aims to answer are: * Will additive and synergistic effects be observed when using a combination of glofitamab and pirtobrutinib? * Will this combination be safe and lead to high complete- and remission rates with no residual disease? Pirtobrutinib will be given to all participants as an oral tablet for the duration of the entire study. Participants will receive other treatment in 3 phases: 1. Treatment Ramp-Up 1. Treatment

Trial Details

NCT ID
NCT05833763
Phase
PHASE2
Sponsor
Australasian Leukaemia and Lymphoma Group
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Glofitamab
  • Pirtobrutinib
  • Obinutuzumab
  • Tocilizumab
Locations (sample)
  • Parkville, Victoria, Australia|-37.78333,144.95
  • Nedlands, Western Australia, Australia|-31.98184,115.8073

Key Eligibility Criteria

  • Ages 18 years old or above
  • A confirmed diagnosis of MCL according to World Health Organization (2016) criteria
  • At least one site of measurable disease not previously irradiated (defined as at least one bi-dimensionally measurable nodal lesion of greater than…
  • Life expectancy (in the opinion of the investigator) of greater than or equal to 18 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →